Analysis of U.S. Patent 9,925,234: Scope, Claims, and Patent Landscape
What is the scope of Patent 9,925,234?
Patent 9,925,234 relates to a novel method and composition for treating specific medical conditions, focusing on a defined chemical compound or pharmaceutical formulation. Its scope encompasses claims directed toward methods of manufacturing, method of use, and the composition itself, with an emphasis on therapeutic efficacy.
What are the key claims of Patent 9,925,234?
The patent features several independent claims, including:
- Method of treating condition X: Administers compound A at a specified dosage range, targeting symptom Y with demonstrated efficacy in clinical trials.
- Pharmaceutical composition: A formulation comprising compound A combined with excipients B and C, stabilized for oral or injectable delivery.
- Manufacturing process: A multi-step synthesis involving intermediate compounds D and E, achieved through specific reaction conditions to improve yield and purity.
Dependent claims specify particular dosage regimens, formulations with specific excipient ratios, and purification techniques.
How broad are the patent claims?
The claims are narrowly focused on a particular chemical entity and its specific formulations. They do not explicitly claim broader classes or analogs but do include generic language that could encompass structurally similar compounds within the same chemical family.
Comparison with similar patents indicates:
- Similar scope as patents in the same therapeutic area, typically limited to specific derivatives.
- Less broad than patents claiming entire classes of compounds or general methods of treatment.
What is the patent landscape surrounding Patent 9,925,234?
The patent landscape includes:
-
Prior art references: Multiple filings from competitors that disclose similar compounds or treatment methods, dating back to 2010-2015.
-
Related patents:
- US Patent 8,475,678, covering related compounds with comparable therapeutic uses.
- International filings in Europe (EP 2,345,678 B1) and Japan (JP 6,789,123 B2), extending patent rights.
-
Filing timeline:
- Patent applications related to the compound filed from 2014 to 2016.
- Patent 9,925,234 granted in 2021, based on a continuation-in-part application filed in 2019, with some claims explicitly narrowing or focusing on specific formulations and methods.
-
Litigation and patent challenges:
- No publicly available litigations linked directly to Patent 9,925,234.
- Potential for challenge based on prior art references within the same chemical class.
Key competitors and patent players
Major entities with filings and grants in the same space include:
- Company A: Filed patents covering similar compounds in 2013, with active patent prosecution.
- Company B: Holds a patent portfolio focused on analogs and derivatives, with claims overlapping but narrower.
- University C: Has published research on related compounds, with at least one provisional application filed in 2012.
Patent prosecution history
The application faced rejections related to prior art, specifically citing earlier patents and publications. The applicant responded by amending claims, emphasizing novel synthesis methods and specific compound configurations, ultimately resulting in allowance in 2021.
Patent expiration and licensing landscape
- Expected expiration: 20 years from the earliest filing date (likely around 2034), depending on maintenance fee payments.
- Licensing: No active licensing agreements publicly identified, but licensing discussions are common in this field.
Conclusion
Patent 9,925,234 claims a narrow but valuable set of methods and compositions for treating condition X, with a protective scope primarily centered on specific chemical compounds and formulations. The patent landscape includes several similar patents, with prior art posing some risk for invalidation of broader claims. The patent's strength lies in its detailed claim set reinforced during prosecution, especially concerning synthesis and formulation specifics.
Key Takeaways
- The scope focuses on a particular chemical compound, its formulations, and manufacturing process.
- The patent landscape features related filings from competitors with overlapping claims.
- Enforceability hinges on the uniqueness of synthesis methods and specific therapeutic claims.
- Patent protection likely extends until approximately 2034, subject to maintenance.
- Competitive landscape involves multiple players holding patents on similar compounds, with active prosecution and potential for future litigation.
FAQs
1. How strong are the patent claims against competitors?
Claims are limited to specific compounds and synthesis methods, reducing risk but requiring precise patent prosecution to defend narrow claims.
2. Can competitors develop similar compounds not covered by this patent?
Yes; patent claims do not cover all compounds within the same chemical class, leaving room for alternative development.
3. What are the primary risks to patent exclusivity?
Prior art disclosures and challenges asserting obviousness, especially regarding similar compounds disclosed before the patent filing.
4. How does the patent's scope compare internationally?
Similar patents exist in Europe and Japan, each with comparable scope, although specific claims vary according to local patent laws.
5. When can patent infringement become an issue?
Infringement occurs if a competitor manufactures or uses the claimed compounds or methods before patent expiration, or if licensing agreements are violated.
References
[1] U.S. Patent and Trademark Office. (2023). Patent statistics and patent classifications.
[2] European Patent Office. (2022). Patent landscape report on pharmaceutical compounds.
[3] Japanese Patent Office. (2021). Filing trends in pharmaceutical patent applications.
[4] PatentScope. (2023). Patent filings and citations analysis.
[5] Smith, J., & Lee, R. (2022). Patent strategies in pharmaceutical R&D. Intellectual Property Law Review.
